

Solasia Announces Exclusive Out-Licensing Agreement for episil® oral liquid with Synex in South Korea

Tokyo, Japan, January 30, 2020 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia"), a specialty pharmaceutical company based in Asia, today officially announced that it has entered into an exclusive agreement for the commercialization and promotion of episil® oral liquid (SP-03, hereinafter "episil®") in South Korea, following regulatory approval in the country, with Synex Consulting Ltd. (Headquarters: Seoul, South Korea, hereinafter "Synex").

Solasia has obtained an exclusive license to develop and commercialize episil® in Japan, China, and South Korea from Sweden-based Camurus AB (STO: CAMX). episil® was launched in Japan in 2018 with the approval of the Ministry of Health, Labour and Welfare (MHLW), and in China in 2019 with the approval of the National Medical Products Administration (NMPA, formerly CFDA). In South Korea, episil® has been approved from the National Institute of Medical Device Safety Information (NIDS) in October 2019. Solasia has now entered into an exclusive out-licensing agreement with Synex, which will act as the company's sales partner in South Korea.

The new agreement is expected to contribute to Solasia's earnings over the medium to long term. Solasia is still examining the impact of the agreement on its earnings for the fiscal year ending December 31, 2020, and any such impact will be factored into its corresponding earnings forecasts to be announced with the results for the fiscal year ending December 31, 2019 on February 13, 2020.

About episil®

episil® uses the patented FluidCrystal® technology from Camurus AB, Sweden. It is a lipid-based, preservative-free liquid that adhere to the oral mucosa. Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours*. It provides physical protection to the oral sensitive and ulcerated epithelium. episil® is the only ready-to-use, pocket-sized medical device that manages and relieves oral mucositis, expected helping patients suffering from oral pain to improve the quality of life (QOL). episil® was first registered in Europe in 2009 and is now launched in the United States, Europe, Japan and other countries. episil® oral liquid is registered as Class I medical device in Europe, 510(k) medical device in the United States, and approved as Class II medical device in Japan, China and South Korea.

For more information about episil®, please access Camurus AB, episil® website: <https://www.episil.net/>

* Hadjieva, T et al. Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer 2014, 22:1557–1562

About Solasia

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

For more information about the company, please visit www.solasia.co.jp/en/

About Synex

Synex started as a regulatory consulting firm for healthcare products and has since expanded its service scope continually. We have leveraged those consulting competencies to further boost ourselves to a total market access solution firm for importing and distributing medical products in South Korea.

The firm currently maintains over 100 product licenses for more than 20 global healthcare manufacturers. In addition, in terms of distributing business, Synex not only directly distributes healthcare products to customers including hospitals, wholesalers, and others, but also provides clinical support, technical support, marketing, and logistics toward medical products.

For more information about the company, please visit <http://www.synex.co.kr/>

(Contact)

Solasia Pharma K.K.

Rie Toyoda, Public Relations and Investor Relations

Tel: +81 3 5843 8049 (Japan)

info@solasia.co.jp